These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Attempt with oral immunobiotherapy (broncho-vaxom) and immunochemotherapy (broncho-vaxom + neomycin) for the elimination of bacteria in symptom-free "other Salmonella" carriers.
    Author: Münnich D, Dalmi L.
    Journal: Ther Hung; 1989; 37(4):209-15. PubMed ID: 2631289.
    Abstract:
    Forty-five symptomless "other Salmonella" carriers were treated; stool became negative for Salmonella in 22 of the 25 patients treated with Broncho-Vaxom (88%) and in 16 of the 20 patients treated with Broncho-Vaxom + Neomycin (80%) (who had discharged Salmonella for not longer than one month previously). This result is very favourable when compared to data of references of thoroughly controlled patients according to which 69% was the highest rate of bacterial negativity obtained in the treated patients who discharged "other Salmonellas" for not longer than 1 month. The stool of all 10 patients admitted as symptomless carriers of "other Salmonellas" became negative for bacteria in response to the mentioned therapy (in 6 cases of Group I, and 4 cases of Group II). Treatment was unsuccessful primarily in chronic alcohol addicts and toxicosis cases (13%). The unresponsiveness of the two patients suffering from cholelithiasis and excreting also "other Salmonella" with the bile deserves attention. In such cases the positivity of the bile for Salmonella was a reason for exclusion from the study. Further studies (completed with immunological data) are required to assess the value of Broncho-Vaxom immunobiotherapy, and Broncho-Vaxom + Neomycin immunotherapy.
    [Abstract] [Full Text] [Related] [New Search]